Search

Leptomeningeal metastases (LM) occurs in approximately 5% of individuals diagnosed with metastatic breast cancer (BC). Both systemic and intrathecal (IT) agents can be used for treatment. However, data to support the effectiveness of IT therapy are insufficient. The primary aim of this study was to assess the efficacy and safety of IT therapy in BC patients with LM. This was a retrospective observational study. SPSS version 27 was used for statistical analysis. Kaplan--Meier and Cox regression analyses were used for survival analysis. The study included 14 patients (median age, 52 years). The predominant histopathological t ypes were invasive ductal carcinoma (57%) and invasive lobular carcinoma (36%). In IT treatment, methotrexate was used in 64% of the patients and trastuzumab was used in 36%. Notably, 36% of patients had a partial response, 14% had a stable response, and 5 0% had disease progression. It was found that approximately 50% of patients with positive cerebrospinal fluid (CSF) cytology became negative after treatment. Furthermore, toxicity of grade 2 or higher was observed in 49% of patients. The median progression-free survival duration among patients who received methotrexate was 1.46 months (95% CI, 0.29-2.0) and among those who received trastuzumab was 5.1 months (95% CI, 0-13.1). The median overall survival duration among all patients was 3.8 months. LM is an indicator of poor prognosis among patients with breast cancer. However, IT therapy is one of the few treatment options. IT trastuzumab should be considered as a treatment if leptomeningeal metastases develop in HER2-positive breast cancer. [ABSTRACT FROM AUTHOR]

OBJECTIVE Breast cancer is the most diagnosed cancer in females. Cancer screening programs increase the detection of early-stage breast cancer. This study aimed to assess the long-term outcomes and the effect of adjuvant therapies for recurrence in stage I breast cancer patients. METHODS We recorded clinicopathological and treatment features of the stage I breast cancer patients and evaluated long-term outcomes retrospectively. Kaplan-Meier analysis and Cox regression analysis were used for recurrence and overall survival. RESULTS 308 patients with stage I breast cancer were involved in the study. The average age was 52 (range 21-81). The median follow-up was 99 (12-380) months. Forty-three (14%) patients were aged over 65, and 162 (52.7%) patients were postmenopausal. ER, PR, and HER2 receptor positivity were 78.9%, 60.8%, and 14.3%, respectively. Lumpectomy plus adjuvant radiotherapy was performed in 82.1% of the patients, and mastectomy in 10.7% of the patients for primary treatment. The patients received adjuvant chemotherapy (42.5%) and adjuvant hormonal therapy (79.9%). Recurrence (local-47.8%, metastatic-52.2%) occurred in 23 (7.5%) patients. In multivariate Cox regression analysis, we found that primary treatment (lumpectomy + adjuvant RT or mastectomy) (p=0.614), surgical margin status (p=0.495), adjuvant chemotherapy (p=0.259), and adjuvant hormonal therapy (p=0.289) were not statistically significant factors for recurrence. However, aged over 65 years (p=0.002) was statistically significant. CONCLUSION In this study, we showed long-term outcomes in stage I breast cancer patients. It was shown that the primary treatment type (lumpectomy + adjuvant RT or mastectomy) was not different in terms of recurrence. In addition, it was determined that adjuvant chemotherapy did not provide benefit for recurrence in stage I breast cancer patients in our results. For this reason, in patients with stage I cancer, more care should be taken in the decision of adjuvant therapy. [ABSTRACT FROM AUTHOR]

Simple Summary: We investigated any possible associations between chemokine receptor expression and responses to chemotherapy along with survival outcomes in patients with triple-negative breast cancer with locally advanced disease. Expressions of chemokine receptors were examined after staining surgical specimens using specific antibodies for CCR5, CCR7, CXCR4, and CXCR5. Patients with high CCR5, CCR7, CXCR4, and CXCR5 expression on tumors and high CXCR4 expression on tumor-infiltrating lymphocytes were less likely to have a chemotherapy response compared to others. Patients with residual lymph node metastases after chemotherapy, CCR5, or CXCR4 expressions on tumors have shown a worse outcome compared to others. However, patients with CXCR5 expression on tumor-infiltrating lymphocytes had a better outcome compared to those without. High expression of CXCR4 or CCR5 on tumor was found to be associated with poor prognosis, and CXCR5 on tumor was associated with poor chemotherapy response in the present cohort with locally advanced triple-negative breast cancer. Our results suggest that patients with triple-negative breast cancer could benefit from a chemokine receptor inhibitor therapy. Background: We aim to investigate any possible associations between chemokine receptor expression and responses to neoadjuvant chemotherapy (NAC) along with outcomes in patients with triple-negative breast cancer (TNBC) with locally advanced disease. Method: Expressions of chemokine receptors were examined immunohistochemically after staining archival tissue of surgical specimens (n = 63) using specific antibodies for CCR5, CCR7, CXCR4, and CXCR5. Results: Patients with high CCR5, CCR7, CXCR4, and CXCR5 expression on tumors and high CXCR4 expression on tumor-infiltrating lymphocytes (TILs) were less likely to have a pathological complete response (pCR) or Class 0-I RCB-Index compared to others. Patients with residual lymph node metastases (ypN-positive), high CCR5TM(tumor), and high CXCR4TM expressions had an increased hazard ratio (HR) compared to others (DFS: HR = 2.655 [1.029–6.852]; DSS: HR = 2.763 [1.008–7.574]), (DFS: HR = 2.036 [0.805–5.148]; DSS: HR = 2.689 [1.020–7.090]), and (DFS: HR = 2.908 [1.080–7.829]; DSS: HR = 2.132 (0.778–5.846)), respectively. However, patients without CXCR5TIL expression had an increased HR compared to those with CXCR5TIL (DFS: 2.838 [1.266–6.362]; DSS: 4.211 [1.770–10.016]). Conclusions: High expression of CXCR4TM and CCR5TM was found to be associated with poor prognosis, and CXCR5TM was associated with poor chemotherapy response in the present cohort with locally advanced TNBC. Our results suggest that patients with TNBC could benefit from a chemokine receptor inhibitor therapy containing neoadjuvant chemotherapy protocols. [ABSTRACT FROM AUTHOR]

Copyright of Selcuk University Medical Journal is the property of Selcuk University Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE This study assessed the efficacy of chemotherapeutic agents used in combination with bevacizumab in patients with metastatic ovarian cancer who could not receive platinum. METHODS The study is a retrospective observational study. Kaplan-Meier and Cox regression methods were used for statistical analysis. RESULTS The most common metastatic sites among the 60 patients were the peritoneum (91.7%), liver (51.7%), and lung (20%). As a single agent combined with bevacizumab, 29 (48.3%) patients received paclitaxel, 16 (26.7%) received liposomal doxorubicin, and 15 (25%) received gemcitabine. The median progression- free survival was 7.5 months (95% CI, 3.4-11.4), and the median overall survival was 14.4 months (95% CI, 9.3-19.4). Among the factors that affected overall survival, the number of metastasis sites (p=0.01) was statistically significant. The type of chemotherapy used with bevacizumab (p=0.55), age (p=0.057), liver metastasis (p=0.28), lung metastasis (p=0.19), bone metastasis (p=0.13), and brain metastasis (p=0.12) were not statistically significant. CONCLUSION Single-agent chemotherapy drugs used with bevacizumab demonstrated similar efficacy against ovarian cancer. Patients' performance scores, previous treatment regimens, and side effect profiles should be considered before administering any specific chemotherapy agent in combination with bevacizumab. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the effectiveness of hormonal therapy (HT) in patients with recurrent adult ovary granulosa cell tumors. Methods: The clinical and treatments features of the patients who received HT were studied retrospectively. The efficacy and safety of HT were evaluated. The Kaplan-Meier technique was used to conduct survival analysis. Results: The research involved a total of thirteen patients. The median age of the participants was 49 years (range: 34-61). Since diagnosis, the median number of surgeries has been three (range: 2-8). At least one chemotherapy regimen has been administered to 12 (92.3%) patients. Ten of the patients (76.9%) had at least two metastatic areas. Lung metastases were found in two (15.4%) of the patients. Inhibin B levels were elevated in 81.2% of patients before hormone treatment. The patients received different HTs (Leuprolide acetate + anastrozole-three patients, leuprolide acetate + tamoxifen-six patients, only anastrozole-three patients, only tamoxifen-one patients). The median progression-free survival was found 17.7 months (95 % CI: 14.7-20.6). In four (33.4%) patients, an overall response (complete or partial) was identified. A stable response was observed in eight (66.7%) patients. Conclusions: HT is effective in pretreated individuals with recurrent ovarian granulosa cell tumors, according to this research. Despite the limited number of patients and treatment variability, disease control was achieved in all patients. Also, we found that Inhibin B levels were associated with treatment response. [ABSTRACT FROM AUTHOR]